Dulaglutide was Lilly's weekly GLP-1 long before Mounjaro or Zepbound existed. For type 2 diabetes patients, it quietly racked up one of the most impressive cardiovascular outcome datasets in the class.
Last Updated
April 17, 2026
2014
Trulicity FDA approval, Lilly's first weekly GLP-1 receptor agonist
12%
Reduction in major cardiovascular events in the REWIND trial (9,901 patients)
1.5%
Average HbA1c reduction at the 4.5 mg dose (AWARD-11 trial)
10M+
US prescriptions in 2023, the 63rd most prescribed medication that year
🔑 Key Takeaways
- Dulaglutide (brand Trulicity, Eli Lilly) is a once-weekly GLP-1 receptor agonist approved for type 2 diabetes in adults and children age 10 and older
- FDA approved 2014 for T2D, with a cardiovascular outcomes indication added in 2020 and high-dose expansion (3.0 and 4.5 mg) approved the same year
- Not FDA-approved for weight loss, but often produces ~5 to 8 pounds of weight loss as a side effect of T2D treatment. Sometimes prescribed off-label when Wegovy or Zepbound are inaccessible
- REWIND trial showed 12% MACE reduction over 5.4 years, the strongest cardiovascular evidence of any weekly GLP-1 in lower-risk T2D patients
- Dose options: 0.75, 1.5, 3.0, 4.5 mg once weekly. Higher doses approved 2020 after AWARD-11 showed better HbA1c and weight loss
- Structure is unique: GLP-1 covalently fused to an IgG4 antibody Fc fragment, which extends half-life and allows weekly dosing
- Not approved for type 1 diabetes or diabetic ketoacidosis. Not a substitute for insulin in any condition
- Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2
This page covers dulaglutide in 2026: what it is, how it works, dosing, side effects, contraindications, drug interactions, cost, how it compares to newer GLP-1s like semaglutide and tirzepatide, and when it still fits a patient.
What Is Dulaglutide?
A weekly GLP-1 agonist with an antibody backbone.
Dulaglutide is a once-weekly GLP-1 receptor agonist developed by Eli Lilly, sold under the brand name Trulicity. Structurally it is unusual: two GLP-1(7-37) peptide analogs covalently fused to the Fc fragment of a modified human IgG4 antibody. This antibody backbone protects the peptide from enzymatic degradation and extends its half-life significantly, which is what makes once-weekly dosing possible.
Dulaglutide at a Glance
- Brand name: Trulicity (Eli Lilly)
- Chemical formula: C2646H4044N704O836S18
- Molar mass: 59,670 g/mol (a very large molecule by peptide standards)
- Dosing: Once weekly subcutaneous injection
- Available doses: 0.75, 1.5, 3.0, 4.5 mg
- FDA approvals: Type 2 diabetes September 2014, cardiovascular risk reduction 2020, higher 3.0 and 4.5 mg doses 2020 (based on AWARD-11)
Dulaglutide launched in the US at the 0.75 and 1.5 mg doses. The 2020 expansion to 3.0 and 4.5 mg responded to AWARD-11 trial data showing superior HbA1c reduction at higher doses. In 2023, dulaglutide was the 63rd most prescribed medication in the United States, with more than 10 million prescriptions filled.
What Dulaglutide Is Used For
Two approved indications, one common off-label use.
- Type 2 diabetes (primary indication): Approved for adults and children 10 and older to improve glycemic control, alongside diet and exercise. Can be used as monotherapy or combined with metformin, sulfonylureas, thiazolidinediones, or insulin.
- Cardiovascular risk reduction: Approved since 2020 for reducing major adverse cardiovascular events (cardiovascular death, heart attack, stroke) in adults with T2D who have established cardiovascular disease or multiple cardiovascular risk factors. REWIND demonstrated benefit even in lower-risk T2D patients, which is unusual in the class.
- Weight loss (off-label): Not FDA-approved for weight management. Most patients lose roughly 5 to 8 pounds at the 1.5 mg dose and slightly more at higher doses, but this is a side effect rather than an indication. For dedicated weight management, Wegovy or Zepbound are the on-label choices.
- Not indicated for: Type 1 diabetes, diabetic ketoacidosis, pediatric patients under 10, or pregnancy.
How Dulaglutide Works
Same GLP-1 mechanism, weekly delivery.
Dulaglutide binds and activates the GLP-1 receptor. GLP-1 is normally secreted by L cells of the gastrointestinal mucosa in response to a meal. Activating the receptor produces four major effects:
- Glucose-dependent insulin secretion: Beta cells release more insulin, but only when blood glucose is elevated. This is why hypoglycemia risk is low when dulaglutide is used without insulin or sulfonylureas.
- Glucagon suppression: Alpha cells reduce glucagon release, preventing over-production of glucose from the liver.
- Slowed gastric emptying: Food moves through the stomach more slowly, flattening post-meal glucose spikes and producing longer satiety.
- Central appetite reduction: GLP-1 receptors in the hypothalamus reduce hunger signaling, which accounts for the modest weight loss seen in dulaglutide patients.
The antibody Fc backbone is what differentiates dulaglutide structurally. The Fc fragment recycles via neonatal Fc receptors, which extends plasma half-life to several days. This is the engineering reason dulaglutide can be dosed weekly while endogenous GLP-1 lasts 1 to 2 minutes.
Dulaglutide Dosage and How to Use It
Weekly subcutaneous injection, start low, titrate slowly.
Standard titration
Dulaglutide Dose Schedule
- Starting dose: 0.75 mg once weekly for 4 weeks
- Step up: 1.5 mg once weekly (standard maintenance dose for most patients)
- For inadequate glycemic control: Increase to 3.0 mg once weekly after at least 4 weeks
- Maximum dose: 4.5 mg once weekly after at least 4 weeks on 3.0 mg
Higher doses (3.0 and 4.5 mg) produce roughly 1.5% HbA1c reduction compared to 1% at the 1.5 mg dose, per AWARD-11. Weight loss is slightly greater at higher doses.
Administration
- Pre-filled single-use pen (Trulicity) that self-primes and auto-injects.
- Inject subcutaneously into the abdomen, thigh, or upper arm. Rotate sites.
- Take on the same day each week, at any time of day, with or without food.
- If needed, the day of weekly dosing can be changed as long as the last dose was at least 3 days ago.
Missed dose
- If a dose is missed and more than 3 days remain before the next scheduled dose, take it as soon as remembered.
- If less than 3 days remain, skip the missed dose and resume the regular schedule.
- Do not inject two doses within 3 days of each other.
Storage
- Unopened pens: Refrigerate at 2 to 8°C (36 to 46°F). Do not freeze.
- Room temperature: Can be stored up to 14 days at room temperature (up to 30°C / 86°F).
- Protect from light. Discard any pen that has been frozen or exposed to high heat.
Dulaglutide Side Effects
Similar GI profile to the class, typically well-tolerated at standard doses.
| Side effect | Frequency | Notes |
|---|---|---|
| Nausea | ~21% | Higher at 3.0 and 4.5 mg. Worst in first 4 weeks |
| Diarrhea | ~13% | Typically mild and transient |
| Vomiting | ~12% | Occurs mostly during dose escalation |
| Abdominal pain, indigestion | ~9% | Improves with continued use |
| Decreased appetite | ~5-8% | Related to weight loss effect |
| Fatigue | ~5% | More common in first weeks |
| Mild heart rate increase | 2-3 bpm average | Class effect, generally not clinically significant |
| Hypoglycemia | Higher with insulin or sulfonylureas | Consider reducing other diabetes medications |
Serious Side Effects (Rare)
- Acute pancreatitis: Severe, persistent abdominal pain, sometimes with vomiting. Stop the drug and seek urgent evaluation.
- Hypersensitivity reactions: Swelling of face, lips, or throat, or severe rash. Discontinue immediately.
- Renal impairment: Severe vomiting and dehydration can precipitate acute kidney injury. Aggressive hydration during the first weeks is essential.
- Thyroid C-cell tumors: An early high-dose safety signal led to a boxed warning against use in patients with personal or family history of MTC or MEN2. Clinical relevance in humans remains unconfirmed despite millions of patient-years of exposure.
- Gallbladder disease: Rapid weight loss increases gallstone risk across the class. Right-upper-quadrant pain warrants imaging.
- Elevated pancreatic enzymes: Monitor if symptoms emerge.
Who Should Not Use Dulaglutide
Do NOT Use Dulaglutide If You Have:
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2)
- History of pancreatitis
- Type 1 diabetes or diabetic ketoacidosis
- Severe gastroparesis or other significant GI motility disorder
- Severe hypersensitivity to dulaglutide or any component of the formulation
- Severe renal impairment (caution advised, dose adjustment may be needed)
- Pregnancy or active breastfeeding
Dulaglutide Drug Interactions
Similar to the rest of the class.
- Insulin and sulfonylureas: Risk of hypoglycemia rises substantially. Physicians usually reduce the dose of insulin or sulfonylurea when adding dulaglutide.
- Oral medications: Delayed gastric emptying can affect absorption of oral drugs. The clinical effect is usually modest for dulaglutide (less pronounced than for some other GLP-1s) but worth considering for narrow-therapeutic-window drugs.
- Oral contraceptives: Generally not considered meaningfully affected by dulaglutide, but backup contraception during titration is reasonable for patients relying solely on oral contraceptives.
- Warfarin: Monitor INR more frequently during the first 3 months of dulaglutide use, as weight changes and diet shifts can affect anticoagulation.
- Alcohol: No direct drug interaction, but most patients tolerate alcohol less well on dulaglutide.
Pregnancy, Breastfeeding, and Pediatric Use
- Pregnancy: Not recommended. Discontinue at least 2 months before planned conception. The weekly half-life means the drug persists in the body longer than daily GLP-1s.
- Breastfeeding: Safety data in breast milk is limited. Discuss alternatives with your prescriber.
- Pediatric: Approved for children 10 and older with type 2 diabetes. Not approved for pediatric weight management, and not studied in children with type 1 diabetes.
- Geriatric: No specific dose adjustment required in elderly patients with normal renal function. Caution in patients over 75 due to volume depletion risk.
Dulaglutide Cost and Insurance
| Option | Monthly cost (cash) | Notes |
|---|---|---|
| Trulicity (list price) | ~$977 | Without insurance or manufacturer program |
| Commercial insurance with T2D diagnosis | $25-$250 | Usually covered with prior authorization for T2D |
| Medicare Part D | Variable | Covered for T2D, not for weight loss |
| Lilly Trulicity Savings Card | As low as $25/month | Commercial insurance required, income limits may apply |
Insurance coverage for dulaglutide is significantly easier than for weight-loss-indicated GLP-1s, because the T2D indication has been established for over a decade and most commercial plans cover it with standard prior authorization.
Dulaglutide vs Other GLP-1 Drugs
| Drug | Dose frequency | Primary use | Weight loss (T2D context) | CV outcome data |
|---|---|---|---|---|
| Dulaglutide (Trulicity) | Weekly | T2D + CV risk reduction | ~3-5% | REWIND: 12% MACE reduction in lower-risk T2D |
| Semaglutide (Ozempic/Wegovy) | Weekly | T2D (Ozempic), weight loss (Wegovy), CV (SELECT) | ~8-15% | SELECT: 20% MACE reduction in obesity without T2D |
| Liraglutide (Victoza/Saxenda) | Daily | T2D (Victoza), weight loss (Saxenda) | ~5-8% | LEADER: MACE reduction in T2D with CVD |
| Tirzepatide (Mounjaro/Zepbound) | Weekly | T2D (Mounjaro), weight loss (Zepbound) | ~15-20% | SURPASS CV outcomes data pending; OSA approved 2024 |
| Exenatide (Byetta/Bydureon) | Twice daily or weekly | T2D | ~2-5% | EXSCEL: neutral, no significant MACE benefit |
For a T2D patient without obesity or where maximum weight loss is not the goal, dulaglutide has the advantage of weekly dosing, a strong REWIND cardiovascular dataset even in lower-risk patients, and broad insurance coverage through the T2D indication. For patients where weight loss is a primary concern, semaglutide (Ozempic) or tirzepatide (Mounjaro) typically outperform it.
When Dulaglutide Still Fits in 2026
- T2D with lower CV risk: REWIND is the only trial showing GLP-1 cardiovascular benefit in patients without established CVD. If a patient has T2D and multiple risk factors but no prior event, dulaglutide has the best outcomes data.
- Insurance coverage: Most commercial and Medicare Part D plans cover dulaglutide for T2D without difficulty. Wegovy and Zepbound can face heavier prior authorization hurdles.
- Weekly dosing preference: If a patient will not tolerate daily injections but semaglutide or tirzepatide is inaccessible, dulaglutide is a reasonable weekly option.
- Step therapy: Some insurance plans require a dulaglutide trial before approving semaglutide or tirzepatide.
- Established tolerance: Patients already stable on dulaglutide who have reached good glycemic control and acceptable tolerance often have little reason to switch.
For patients whose primary goal is weight loss rather than T2D management, see our weight loss drugs overview and the weight loss injections comparison, both of which cover semaglutide and tirzepatide as the stronger choices.
Frequently Asked Questions
What is dulaglutide used for?
Dulaglutide (Trulicity) is FDA-approved for type 2 diabetes in adults and children 10 and older, and for cardiovascular risk reduction in T2D patients. It is not approved for weight loss, although most patients experience modest weight loss as a side effect.
How much weight can you lose on Trulicity?
Typical weight loss on dulaglutide is roughly 5 to 8 pounds at the 1.5 mg dose, with slightly more at the 3.0 or 4.5 mg doses. It is not approved for weight loss. Semaglutide (Wegovy) and tirzepatide (Zepbound) produce significantly more weight loss and are the on-label choices for chronic weight management.
How often do you take dulaglutide?
Once weekly. A single subcutaneous injection on the same day each week, at any time of day, with or without food. The pre-filled pen self-primes and auto-injects.
What is the difference between dulaglutide and semaglutide?
Both are weekly GLP-1 receptor agonists. Dulaglutide is GLP-1 fused to an IgG4 Fc antibody fragment (from Eli Lilly). Semaglutide is a modified GLP-1 peptide with a fatty acid chain (from Novo Nordisk). Semaglutide produces more weight loss and has stronger HbA1c reduction at comparable doses. Dulaglutide has a stronger cardiovascular outcome dataset in lower-risk T2D patients (REWIND).
What are the most common dulaglutide side effects?
Nausea (21%), diarrhea (13%), vomiting (12%), abdominal pain, decreased appetite, and fatigue. Most are worst in the first 4 weeks and fade at the maintenance dose. Slower titration helps when side effects are strong.
Does dulaglutide lower blood pressure?
Modestly. Dulaglutide produces small reductions in systolic blood pressure, roughly 2 to 4 mmHg, which is consistent across the GLP-1 class. A small heart rate increase of 2 to 3 bpm is also typical. Neither effect is usually clinically significant.
Is Trulicity covered by insurance?
Yes, most commercial insurance and Medicare Part D plans cover Trulicity for type 2 diabetes. Prior authorization is common but typically approved. Coverage for weight loss is generally denied because the weight-loss indication does not apply to dulaglutide. The Lilly Trulicity Savings Card can reduce copays to as low as $25/month for eligible commercial insurance holders.
Can dulaglutide be used with insulin?
Yes, dulaglutide can be combined with insulin. Hypoglycemia risk rises, so insulin doses are usually reduced when starting dulaglutide. This combination is common in T2D patients who are not adequately controlled on insulin alone.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Dulaglutide is a prescription medication that should be used under physician supervision. Individual results vary. Consult a licensed healthcare provider to determine whether dulaglutide is appropriate for your health profile.